Virtu Financial’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $752K | Buy |
23,099
+13,883
| +151% | +$446K | 0.03% | 418 |
|
|
2025
Q4 | $324K | Sell |
9,216
-16,619
| -64% | -$589K | 0.01% | 816 |
|
|
2025
Q3 | $679K | Buy |
+25,835
| New | +$771K | 0.04% | 451 |
|
|
2025
Q2 | – | Sell |
-14,350
| Closed | -$347K | – | 2065 |
|
|
2025
Q1 | $347K | Sell |
14,350
-28,263
| -66% | -$893K | 0.02% | 614 |
|
|
2024
Q4 | $1.72M | Buy |
+42,613
| New | +$2.43M | 0.09% | 184 |
|
|
2024
Q3 | – | Sell |
-27,569
| Closed | -$1.46M | – | 1923 |
|
|
2024
Q2 | $1.46M | Buy |
+27,569
| New | +$1.81M | 0.1% | 201 |
|
|
2024
Q1 | – | Sell |
-29,394
| Closed | -$547K | – | 2142 |
|
|
2023
Q4 | $547K | Buy |
29,394
+3,866
| +15% | +$50.6K | 0.04% | 381 |
|
|
2023
Q3 | $283K | Sell |
25,528
-52,701
| -67% | -$754K | 0.03% | 530 |
|
|
2023
Q2 | $1.27M | Buy |
+78,229
| New | +$1.64M | 0.1% | 164 |
|
|
2022
Q4 | – | Sell |
-16,941
| Closed | -$46K | – | 2171 |
|
|
2022
Q3 | $46K | Buy |
+16,941
| New | +$55.5K | ﹤0.01% | 1223 |
|
|
2022
Q1 | – | Sell |
-12,633
| Closed | -$58K | – | 2069 |
|
|
2021
Q4 | $58K | Buy |
+12,633
| New | +$70.8K | 0.01% | 1306 |
|
|
2021
Q3 | – | Sell |
-22,929
| Closed | -$137K | – | 1998 |
|
|
2021
Q2 | $137K | Buy |
+22,929
| New | +$136K | 0.01% | 1119 |
|
|
2021
Q1 | – | Sell |
-37,152
| Closed | -$209K | – | 2051 |
|
|
2020
Q4 | $209K | Buy |
+37,152
| New | +$225K | 0.02% | 833 |
|
|
2020
Q3 | – | Sell |
-12,761
| Closed | -$92K | – | 1549 |
|
|
2020
Q2 | $92K | Buy |
+12,761
| New | +$84.7K | 0.01% | 904 |
|
|
2019
Q4 | – | Sell |
-12,071
| Closed | -$83K | – | 1889 |
|
|
2019
Q3 | $83K | Sell |
12,071
-8,165
| -40% | -$60.6K | 0.01% | 1120 |
|
|
2019
Q2 | $168K | Sell |
20,236
-143,546
| -88% | -$1.23M | 0.01% | 1056 |
|
|
2019
Q1 | $1.63M | Buy |
163,782
+146,438
| +844% | +$1.23M | 0.09% | 184 |
|
|
2018
Q4 | $133K | Sell |
17,344
-9,729
| -36% | -$116K | 0.01% | 1065 |
|
|
2018
Q3 | $472K | Sell |
27,073
-29,460
| -52% | -$351K | 0.03% | 622 |
|
|
2018
Q2 | $536K | Buy |
+56,533
| New | +$376K | 0.03% | 752 |
|
|
2017
Q4 | – | Sell |
-36,588
| Closed | -$70K | – | 3058 |
|
|
2017
Q3 | $70K | Buy |
+36,588
| New | +$41.6K | ﹤0.01% | 2162 |
|
Other funds holding VKTX
VCM
VPM
Virtu Financial's VKTX Position: Q1 2026 in Review
Virtu Financial increased its Viking Therapeutics (VKTX) stake by 151% in Q1 2026, buying an estimated $446K and bringing the position to 23,099 shares worth $752K. The position accounts for 0.03% of the portfolio, ranked #418.
Virtu Financial first reported a position in VKTX in Q3 2017 and has held it in 21 quarters since. The position peaked at $1.72M in Q4 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Virtu Financial held 23,099 shares of Viking Therapeutics worth $752K as of Q1 2026.
- Virtu Financial bought 13,883 Viking Therapeutics shares in Q1 2026, an estimated $446K.
- Viking Therapeutics made up 0.03% of Virtu Financial's portfolio in Q1 2026, its #418 holding.
- Virtu Financial first reported a position in Viking Therapeutics in Q3 2017 and has held it in 21 quarters since.
- Virtu Financial's Viking Therapeutics position peaked at $1.72M in Q4 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.